OTCMKTS:AITB - AIT Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.50 -0.10 (-2.17 %) (As of 03/21/2019 01:24 AM ET)Previous Close$4.60Today's Range$4.50 - $4.7952-Week Range$2.05 - $5.50Volume19,055 shsAverage Volume7,131 shsMarket Capitalization$38.70 millionP/E Ratio-1.50Dividend YieldN/ABeta-0.32 ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email AIT Therapeutics, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was founded in 2011 and is based in Garden City, New York. Receive AITB News and Ratings via Email Sign-up to receive the latest news and ratings for AITB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:AITB Previous Symbol CUSIPN/A CIKN/A Webwww.ait-therapeutics.com Phone972-8684-3313Debt Debt-to-Equity RatioN/A Current Ratio2.17 Quick Ratio2.17Price-To-Earnings Trailing P/E Ratio-1.50 Forward P/E Ratio-5.77 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($3.01) Net Income$-18,040,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-100.76%Miscellaneous EmployeesN/A Outstanding Shares8,599,000Market Cap$38.70 million Next Earnings Date6/13/2019 (Estimated) OptionableNot Optionable AIT Therapeutics (OTCMKTS:AITB) Frequently Asked Questions What is AIT Therapeutics' stock symbol? AIT Therapeutics trades on the OTCMKTS under the ticker symbol "AITB." How were AIT Therapeutics' earnings last quarter? AIT Therapeutics Inc (OTCMKTS:AITB) posted its earnings results on Wednesday, February, 13th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of ($0.21) by $0.32. View AIT Therapeutics' Earnings History. When is AIT Therapeutics' next earnings date? AIT Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, June 13th 2019. View Earnings Estimates for AIT Therapeutics. Has AIT Therapeutics been receiving favorable news coverage? News headlines about AITB stock have trended somewhat negative on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. AIT Therapeutics earned a news sentiment score of -1.5 on InfoTrie's scale. They also gave media stories about the company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an effect on the company's share price in the next several days. Who are some of AIT Therapeutics' key competitors? Some companies that are related to AIT Therapeutics include Sensus Healthcare (SRTS), RenovaCare (RCAR), T2 Biosystems (TTOO), Alphatec (ATEC), STRATA Skin Sciences (SSKN), iCAD (ICAD), Endologix (ELGX), Apollo Endosurgery (APEN), Titan Medical (TMDI), CAS Medical Systems (CASM), Spectral Medical (EDTXF), Invo Bioscience (IVOB), Motus GI (MOTS), Arch Therapeutics (ARTH) and Repro-Med Systems (REPR). What other stocks do shareholders of AIT Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other AIT Therapeutics investors own include Allena Pharmaceuticals (ALNA), Harvard Bioscience (HBIO), Constellation Brands (STZ), Pieris Pharmaceuticals (PIRS), Obseva (OBSV), Cisco Systems (CSCO), General Electric (GE), Aurora Cannabis (ACBFF), Veru (VERU) and NVIDIA (NVDA). Who are AIT Therapeutics' key executives? AIT Therapeutics' management team includes the folowing people: Mr. Steven Adam Lisi, CEO & Chairman (Age 48)Mr. Amir Avniel, Co-Founder, Pres, COO & Director (Age 45)Mr. Douglas J. Beck, Chief Financial Officer (Age 58)Prof. Asher Tal M.D., Sr. VP of Clinical Research & Member of Scientific Advisory BoardDr. Giora Davidai M.D., Chief Medical Officer How do I buy shares of AIT Therapeutics? Shares of AITB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is AIT Therapeutics' stock price today? One share of AITB stock can currently be purchased for approximately $4.50. How big of a company is AIT Therapeutics? AIT Therapeutics has a market capitalization of $38.70 million. The company earns $-18,040,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. What is AIT Therapeutics' official website? The official website for AIT Therapeutics is http://www.ait-therapeutics.com. How can I contact AIT Therapeutics? AIT Therapeutics' mailing address is 2 ILAN RAMON SCIENCE PARK, NESS ZIONA L3, 7403635. The company can be reached via phone at 972-8684-3313. MarketBeat Community Rating for AIT Therapeutics (OTCMKTS AITB)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 66 (Vote Outperform)Underperform Votes: 81 (Vote Underperform)Total Votes: 147MarketBeat's community ratings are surveys of what our community members think about AIT Therapeutics and other stocks. Vote "Outperform" if you believe AITB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AITB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/21/2019 by MarketBeat.com StaffFeatured Article: When is a capital gain realized?